Aligos Therapeutics

Aligos Therapeutics’ ALG-055009 Achieves Positive Topline Results in Phase 2a HERALD Study for MASH

September 21, 2024

•

Fineline Cube

Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive topline results from its Phase 2a HERALD study for ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH). The study, which is the first to demonstrate the benefits of…
Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy

July 23, 2024

•

Fineline Cube

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos’ ALG-000184 with Amoytop’s Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB)…

Fineline Info & Tech